{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:15:53Z","timestamp":1790795753809,"version":"4.1.0"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"21","license":[{"start":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T00:00:00Z","timestamp":1533859200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T00:00:00Z","timestamp":1533859200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["ERC-2014-AdG-671231-HEPCIR"],"award-info":[{"award-number":["ERC-2014-AdG-671231-HEPCIR"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["Infect-ERA hepBccc"],"award-info":[{"award-number":["Infect-ERA hepBccc"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010677","name":"H2020 Health","doi-asserted-by":"publisher","award":["Hep-CAR 667273"],"award-info":[{"award-number":["Hep-CAR 667273"]}],"id":[{"id":"10.13039\/100010677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","award":["2015\/1099"],"award-info":[{"award-number":["2015\/1099"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","award":["ECTZ50121"],"award-info":[{"award-number":["ECTZ50121"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur le Cancer","doi-asserted-by":"publisher","award":["ARC IHU201301187"],"award-info":[{"award-number":["ARC IHU201301187"]}],"id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R03AI131066"],"award-info":[{"award-number":["R03AI131066"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["201411MFE-338606-245517"],"award-info":[{"award-number":["201411MFE-338606-245517"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00018-018-2892-y","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T10:42:16Z","timestamp":1533897736000},"page":"3895-3905","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["The functional role of sodium taurocholate cotransporting polypeptide NTCP in the life cycle of hepatitis B, C and D viruses"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7835-9468","authenticated-orcid":false,"given":"Carla","family":"Eller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2273-2267","authenticated-orcid":false,"given":"Laura","family":"Heydmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2474-1834","authenticated-orcid":false,"given":"Che C.","family":"Colpitts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9022-5611","authenticated-orcid":false,"given":"Eloi R.","family":"Verrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7281-4511","authenticated-orcid":false,"given":"Catherine","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8864-2168","authenticated-orcid":false,"given":"Thomas F.","family":"Baumert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,10]]},"reference":[{"key":"2892_CR1","unstructured":"World Health Organization (2016) Global health sector strategy on viral hepatitis 2016\u20132021. Towards ending viral hepatitis. World Health Organization. http:\/\/www.who.int\/iris\/handle\/10665\/246177"},{"key":"2892_CR2","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"A Schweitzer","year":"2015","unstructured":"Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ (2015) Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet 386:1546\u20131555. https:\/\/doi.org\/10.1016\/S0140-6736(15)61412-X","journal-title":"Lancet"},{"key":"2892_CR3","unstructured":"World Health Organization (2017) Global hepatitis report 2017. World Health Organization. License: CC BY-NC-SA 3.0 IGO. http:\/\/www.who.int\/iris\/handle\/10665\/255016"},{"key":"2892_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4172\/2332-0877.1000271","volume":"4","author":"P Sultanik","year":"2016","unstructured":"Sultanik P, Pol S (2016) Hepatitis delta virus: epidemiology, natural course and treatment. J Infect Dis Ther 4:2\u20137. https:\/\/doi.org\/10.4172\/2332-0877.1000271","journal-title":"J Infect Dis Ther"},{"key":"2892_CR5","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1056\/NEJMp1401833","volume":"370","author":"RT Chung","year":"2014","unstructured":"Chung RT, Baumert TF (2014) Curing chronic hepatitis C\u2014the arc of a medical triumph. New Engl J Med 370:1576\u20131578. https:\/\/doi.org\/10.1056\/NEJMp1401833","journal-title":"New Engl J Med"},{"key":"2892_CR6","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","volume":"126","author":"B Werle-Lapostolle","year":"2004","unstructured":"Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WE, Xiong S, Brosgart CL, Chen S, Gibbs CS, Zoulim F (2004) Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126:1750\u20131758. https:\/\/doi.org\/10.1053\/j.gastro.2004.03.018","journal-title":"Gastroenterology"},{"key":"2892_CR7","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/hep.29320","volume":"66","author":"GV Papatheodoridis","year":"2017","unstructured":"Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, Van Boemmel F, Calleja JL, Sypsa V, Goulis J, Manolakopoulos S, Loglio A, Siakavellas S, Kesk\u0131n O, Gatselis N, Hansen BE, Lehretz M, De Revilla J, Savvidou S, Kourikou A, Vlachogiannakos I, Galanis K, Yurdaydin C, Berg T, Colombo M, Esteban R, Janssen HLA, Lampertico P (2017) The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology 66:1444\u20131453. https:\/\/doi.org\/10.1002\/hep.29320","journal-title":"Hepatology"},{"key":"2892_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-017-0815-7","volume":"15","author":"TF Baumert","year":"2017","unstructured":"Baumert TF, J\u00fchling F, Ono A, Hoshida Y (2017) Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. BMC Med 15:1\u201310. https:\/\/doi.org\/10.1186\/s12916-017-0815-7","journal-title":"BMC Med"},{"key":"2892_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.coviro.2015.07.009","volume":"14","author":"TF Baumert","year":"2015","unstructured":"Baumert TF, Verrier ER, Nassal M, Chung RT, Zeisel MB (2015) Host-targeting agents for treatment of hepatitis B virus infection. Curr Opin Virol 14:41\u201346. https:\/\/doi.org\/10.1016\/j.coviro.2015.07.009","journal-title":"Curr Opin Virol"},{"key":"2892_CR10","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nbt.3179","volume":"33","author":"L Mailly","year":"2015","unstructured":"Mailly L, Xiao F, Lupberger J, Wilson GK, Aubert P, Duong FHT, Calabrese D, Leboeuf C, Fofana I, Thumann C, Bandiera S, L\u00fctgehetmann M, Volz T, Davis C, Harris HJ, Mee CJ, Girardi E, Chane-Woon-Ming B, Ericsson M, Fletcher N, Bartenschlager R, Pessaux P, Vercauteren K, Meuleman P, Villa P, Kaderali L, Pfeffer S, Heim MH, Neunlist M, Zeisel MB, Dandri M, McKeating JA, Robinet E, Baumert TF (2015) Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. Nat Biotechnol 33:549\u2013554. https:\/\/doi.org\/10.1038\/nbt.3179","journal-title":"Nat Biotechnol"},{"key":"2892_CR11","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/S0140-6736(17)30043-0","volume":"389","author":"MB Zeisel","year":"2017","unstructured":"Zeisel MB, Baumert TF (2017) Clinical development of hepatitis C virus host-targeting agents. Lancet 389:674\u2013675. https:\/\/doi.org\/10.1016\/S0140-6736(17)30043-0","journal-title":"Lancet"},{"key":"2892_CR12","doi-asserted-by":"publisher","first-page":"e000049","DOI":"10.7554\/eLife.00049","volume":"1","author":"H Yan","year":"2012","unstructured":"Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W (2012) Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 1:e000049. https:\/\/doi.org\/10.7554\/eLife.00049","journal-title":"Elife"},{"key":"2892_CR13","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","volume":"146","author":"Y Ni","year":"2014","unstructured":"Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, F\u00e4lth M, Stindt J, K\u00f6niger C, Nassal M, Kubitz R, S\u00fcltmann H, Urban S (2014) Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 146:1070\u20131083. https:\/\/doi.org\/10.1053\/j.gastro.2013.12.024","journal-title":"Gastroenterology"},{"key":"2892_CR14","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jhep.2012.12.008","volume":"58","author":"T Volz","year":"2013","unstructured":"Volz T, Allweiss L, Ben \u1e3eBarek M, Warlich M, Lohse AW, Pollok JM, Alexandrov A, Urban S, Petersen J, L\u00fctgehetmann M, Dandri M (2013) The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol 58:861\u2013867. https:\/\/doi.org\/10.1016\/j.jhep.2012.12.008","journal-title":"J Hepatol"},{"key":"2892_CR15","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1002\/hep.26982","volume":"59","author":"K Watashi","year":"2014","unstructured":"Watashi K, Sluder A, Daito T, Matsunaga S, Ryo A, Nagamori S, Iwamoto M, Nakajima S, Tsukuda S, Borroto-Esoda K, Sugiyama M, Tanaka Y, Kanai Y, Kusuhara H, Mizokami M, Wakita T (2014) Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology 59:1726\u20131737. https:\/\/doi.org\/10.1002\/hep.26982","journal-title":"Hepatology"},{"key":"2892_CR16","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.jhep.2013.11.022","volume":"60","author":"S Nkongolo","year":"2014","unstructured":"Nkongolo S, Ni Y, Lempp FA, Kaufman C, Lindner T, Esser-Nobis K, Lohmann V, Mier W, Mehrle S, Urban S (2014) Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol 60:723\u2013731. https:\/\/doi.org\/10.1016\/j.jhep.2013.11.022","journal-title":"J Hepatol"},{"key":"2892_CR17","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.jhep.2016.11.009","volume":"66","author":"S Shimura","year":"2017","unstructured":"Shimura S, Watashi K, Fukano K, Peel M, Sluder A, Kawai F, Iwamoto M, Tsukuda S, Takeuchi JS, Miyake T, Sugiyama M, Ogasawara Y, Park S, Tanaka Y, Kusuhara H, Mizokami M, Sureau C, Wakita T (2017) Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity. J Hepatol 66:685\u2013692. https:\/\/doi.org\/10.1016\/j.jhep.2016.11.009","journal-title":"J Hepatol"},{"key":"2892_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-15338-0","volume":"7","author":"JM Donkers","year":"2017","unstructured":"Donkers JM, Zehnder B, Van Westen GJP, Kwakkenbos MJ, Ijzerman AP, Elferink RPJO, Beuers U, Urban S, van de Graaf SFJ (2017) Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP. Sci Rep 7:1\u201313. https:\/\/doi.org\/10.1038\/s41598-017-15338-0","journal-title":"Sci Rep"},{"key":"2892_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-20987-w","volume":"8","author":"M Kaneko","year":"2018","unstructured":"Kaneko M, Futamura Y, Tsukuda S, Kondoh Y, Sekine T, Hirano H, Fukano K, Ohashi H, Saso W, Morishita R, Matsunaga S, Kawai F, Ryo A, Park S-Y, Suzuki R, Aizaki H, Ohtani N, Sureau C, Wakita T, Osada H, Watashi K (2018) Chemical array system, a platform to identify novel hepatitis B virus entry inhibitors targeting sodium taurocholate cotransporting polypeptide. Sci Rep 8:1\u201313. https:\/\/doi.org\/10.1038\/s41598-018-20987-w","journal-title":"Sci Rep"},{"key":"2892_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/v8090261","volume":"8","author":"ER Verrier","year":"2016","unstructured":"Verrier ER, Colpitts CC, Schuster C, Zeisel MB, Baumert TF (2016) Cell culture models for the investigation of Hepatitis B and D Virus infection. Viruses 8:1\u201310. https:\/\/doi.org\/10.3390\/v8090261","journal-title":"Viruses"},{"key":"2892_CR21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/B978-0-12-394316-3.00004-1","volume":"70","author":"B D\u00f6ring","year":"2012","unstructured":"D\u00f6ring B, L\u00fctteke T, Geyer J, Petzinger E (2012) The SLC10 carrier family: transport functions and molecular structure. Curr Top Membr 70:105\u2013168. https:\/\/doi.org\/10.1016\/B978-0-12-394316-3.00004-1","journal-title":"Curr Top Membr"},{"key":"2892_CR22","doi-asserted-by":"publisher","first-page":"5641","DOI":"10.3748\/wjg.14.5641","volume":"14","author":"A Esteller","year":"2008","unstructured":"Esteller A (2008) Physiology of bile secretion. World J Gastroenterol 14:5641\u20135649. https:\/\/doi.org\/10.3748\/wjg.14.5641","journal-title":"World J Gastroenterol"},{"key":"2892_CR23","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1002\/hep.510290617","volume":"29","author":"P Podevin","year":"1999","unstructured":"Podevin P, Rosmorduc O, Conti F, Calmus Y, Meier PJ, Poupon R (1999) Bile acids modulate the interferon signalling pathway. Hepatology 29:1840\u20131847","journal-title":"Hepatology"},{"key":"2892_CR24","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1515\/BC.2010.108","volume":"391","author":"D Graf","year":"2010","unstructured":"Graf D, Haselow K, M\u00fcnks I, Bode JG, H\u00e4ussinger D (2010) Inhibition of interferon-a-induced signaling by hyperosmolarity and hydrophobic bile acids. Biol Chem 391:1175\u20131187. https:\/\/doi.org\/10.1515\/BC.2010.108","journal-title":"Biol Chem"},{"key":"2892_CR25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000450983","volume":"35","author":"D Slijepcevic","year":"2017","unstructured":"Slijepcevic D, van de Graaf FJ (2017) Bile acid uptake transporters as targets for therapy. Dig Dis 35:251\u2013258. https:\/\/doi.org\/10.1159\/000450983","journal-title":"Dig Dis"},{"key":"2892_CR26","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00210-006-0043-8","volume":"372","author":"J Geyer","year":"2006","unstructured":"Geyer J, Wilke T, Petzinger E (2006) The solute carrier family SLC10: more than a family of bile acid transporters regarding function and phylogenetic relationships. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 372:413\u2013431. https:\/\/doi.org\/10.1007\/s00210-006-0043-8","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"2892_CR27","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1172\/JCI117091","volume":"93","author":"B Hagenbuch","year":"1994","unstructured":"Hagenbuch B, Meier PJ (1994) Molecular cloning, chromosomal localization, and functional characterization of a human liver Na\u2009+\/bile acid cotransporter. J Clin Invest 93:1326\u20131331","journal-title":"J Clin Invest"},{"key":"2892_CR28","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1002\/hep.510280624","volume":"92","author":"S Mukhopadhyay","year":"1998","unstructured":"Mukhopadhyay S, Ananthanarayanan M, Stieger B, Meier PJ, Suchy FJ, Anwer MS (1998) Sodium taurocholate cotransporting polypeptide is a serine, threonine phosphoprotein and is dephosphorylated by cyclic adenosine monophosphate. Hepatology 92:1629\u20131636","journal-title":"Hepatology"},{"key":"2892_CR29","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.mam.2012.07.004.The","volume":"34","author":"TC da Silva","year":"2013","unstructured":"da Silva TC, Polli JE, Swaan PW (2013) The solute carrier family 10 (SLC10): beyond bile acid transport. Mol Aspects Med 34:252\u2013269. https:\/\/doi.org\/10.1016\/j.mam.2012.07.004.The","journal-title":"Mol Aspects Med"},{"key":"2892_CR30","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nature10450","volume":"478","author":"N-J Hu","year":"2011","unstructured":"Hu N-J, Iwata S, Cameron AD, Drew D (2011) Crystal structure of a bacterial homologue of the bile acid sodium symporter ASBT. Nature 478:408\u2013411. https:\/\/doi.org\/10.1038\/nature10450","journal-title":"Nature"},{"key":"2892_CR31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/978-3-642-14541-4","volume":"201","author":"PA Dawson","year":"2011","unstructured":"Dawson PA (2011) Role of the intestinal bile acid transporters in bile acid and drug disposition. Handb Exp Pharmacol 201:169\u2013203. https:\/\/doi.org\/10.1007\/978-3-642-14541-4","journal-title":"Handb Exp Pharmacol"},{"key":"2892_CR32","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1021\/mp300453k.Structure","volume":"10","author":"Z Dong","year":"2013","unstructured":"Dong Z, Ekins S, Polli JE (2013) Structure activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate co-transporting polypeptide (NTCP). Mol Pharm 10:1008\u20131019. https:\/\/doi.org\/10.1021\/mp300453k.Structure","journal-title":"Mol Pharm"},{"key":"2892_CR33","doi-asserted-by":"publisher","first-page":"G349","DOI":"10.1152\/ajpgi.00417.2002","volume":"284","author":"JYL Chiang","year":"2003","unstructured":"Chiang JYL (2003) Bile acid regulation of hepatic physiology III. Bile acids and nuclear receptors. Am J Physiol Gastrointest Liver Physiol 284:G349\u2013G356","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2892_CR34","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","volume":"6","author":"B Goodwin","year":"2000","unstructured":"Goodwin B, Jones SA, Price RR, Watson MA, Mckee DD, Moore LB, Galardi C, Wilson JG, Lewis MC, Roth ME, Maloney PR, Willson TM, Kliewer SA (2000) A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 6:517\u2013526","journal-title":"Mol Cell"},{"key":"2892_CR35","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S1097-2765(00)00050-2","volume":"6","author":"TT Lu","year":"2000","unstructured":"Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, Mangelsdorf DJ (2000) Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 6:507\u2013515","journal-title":"Mol Cell"},{"key":"2892_CR36","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.2741\/3576","volume":"14","author":"JW Jonker","year":"2009","unstructured":"Jonker JW, Stedman CAM, Liddle C, Downes M (2009) Hepatobiliary ABC transporters: physiology, regulation and implications for disease. Front Biosci 14:4904\u20134920. https:\/\/doi.org\/10.2741\/3576","journal-title":"Front Biosci"},{"key":"2892_CR37","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1194\/jlr.R900010-JLR200","volume":"50","author":"JYL Chiang","year":"2009","unstructured":"Chiang JYL (2009) Bile acids: regulation of synthesis. J Lipid Res 50:1955\u20131966. https:\/\/doi.org\/10.1194\/jlr.R900010-JLR200","journal-title":"J Lipid Res"},{"key":"2892_CR38","doi-asserted-by":"publisher","first-page":"10046","DOI":"10.1074\/jbc.273.16.10046","volume":"273","author":"T Gerloff","year":"1998","unstructured":"Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, Hofmann AF, Meier PJ (1998) The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 273:10046\u201310050","journal-title":"J Biol Chem"},{"key":"2892_CR39","doi-asserted-by":"publisher","first-page":"28857","DOI":"10.1074\/jbc.M011610200","volume":"276","author":"M Ananthanarayanan","year":"2001","unstructured":"Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf DJ, Suchy FJ (2001) Human bile salt export pump promoter is transactivated by the farnesoid X receptor\/bile acid receptor. J Biol Chem 276:28857\u201328865. https:\/\/doi.org\/10.1074\/jbc.M011610200","journal-title":"J Biol Chem"},{"key":"2892_CR40","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1053\/gast.2001.25503","volume":"121","author":"LA Denson","year":"2001","unstructured":"Denson LA, Sturm E, Echevarria W, Zimmerman TL, Makishima M, Mangelsdorf DJ, Karpen SJ (2001) The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology 121:140\u2013147. https:\/\/doi.org\/10.1053\/gast.2001.25503","journal-title":"Gastroenterology"},{"key":"2892_CR41","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1152\/ajpgi.00456.2003","volume":"286","author":"D Jung","year":"2004","unstructured":"Jung D, Hagenbuch B, Fried M, Meier PJ, Kullak-Ublick GA (2004) Role of liver-enriched transcription factors and nuclear receptors in regulating the human, mouse, and rat NTCP gene. Am J Physiol Gastrointest Liver Physiol 286:752\u2013761","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2892_CR42","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1152\/ajpgi.00012.2008","volume":"295","author":"A Geier","year":"2008","unstructured":"Geier A, Martin IV, Dietrich CG, Balasubramaniyan N, Strauch S, Suchy FJ, Gartung C, Trautwein C, Ananthanarayanan M (2008) Hepatocyte nuclear factor-4a is a central transactivator of the mouse Ntcp gene. Am J Physiol Gastrointest Liver Physiol 295:226\u2013233. https:\/\/doi.org\/10.1152\/ajpgi.00012.2008","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2892_CR43","doi-asserted-by":"publisher","first-page":"31416","DOI":"10.1074\/jbc.M204818200","volume":"277","author":"D Li","year":"2002","unstructured":"Li D, Zimmerman TL, Thevananther S, Lee H-Y, Kurie JM, Karpen SJ (2002) Interleukin-1b-mediated suppression of RXR:RAR transactivation of the Ntcp promoter Is JNK-dependent. J Biol Chem 277:31416\u201331422. https:\/\/doi.org\/10.1074\/jbc.M204818200","journal-title":"J Biol Chem"},{"key":"2892_CR44","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.bbrc.2004.07.102","volume":"322","author":"E Siewert","year":"2004","unstructured":"Siewert E, Dietrich CG, Lammert F, Heinrich PC, Matern S, Gartung C, Geier A (2004) Interleukin-6 regulates hepatic transporters during acute-phase response. Biochem Biophys Res Commun 322:232\u2013238. https:\/\/doi.org\/10.1016\/j.bbrc.2004.07.102","journal-title":"Biochem Biophys Res Commun"},{"key":"2892_CR45","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1124\/dmd.108.023630.pump","volume":"37","author":"M Le Vee","year":"2009","unstructured":"Le Vee M, Lecureur V, Stieger B, Fardel O (2009) Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-a or interleukin-6. Drug Metab Dispos 37:685\u2013693. https:\/\/doi.org\/10.1124\/dmd.108.023630.pump","journal-title":"Drug Metab Dispos"},{"key":"2892_CR46","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0168-8278(03)00096-5","volume":"38","author":"G Zollner","year":"2003","unstructured":"Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall H-U, Zatloukal K, Denk H, Trauner M (2003) Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 38:717\u2013727. https:\/\/doi.org\/10.1016\/S0168-8278(03)00096-5","journal-title":"J Hepatol"},{"key":"2892_CR47","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0168-8278(03)00410-0","volume":"39","author":"H Kojima","year":"2003","unstructured":"Kojima H, Nies AT, K\u00f6nig J, Hagmann W, Spring H, Uemura M, Fukui H, Keppler D (2003) Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. J Hepatol 39:693\u2013702. https:\/\/doi.org\/10.1016\/S0168-8278(03)00410-0","journal-title":"J Hepatol"},{"key":"2892_CR48","doi-asserted-by":"crossref","first-page":"56041","DOI":"10.18632\/oncotarget.10241","volume":"8","author":"J Kang","year":"2017","unstructured":"Kang J, Wang J, Cheng J, Cao Z, Chen R, Li H, Liu S, Chen X, Sui J, Lu F (2017) Down-regulation of NTCP expression by cyclin D1 in hepatitis B virus-related hepatocellular carcinoma has clinical significance. Oncotarget 8:56041\u201356050","journal-title":"Oncotarget"},{"key":"2892_CR49","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/hep.27088.Role","volume":"60","author":"MS Anwer","year":"2014","unstructured":"Anwer MS (2014) Role of protein kinase C isoforms in bile formation and cholestasis. Hepatology 60:1090\u20131097. https:\/\/doi.org\/10.1002\/hep.27088.Role","journal-title":"Hepatology"},{"key":"2892_CR50","doi-asserted-by":"crossref","first-page":"17734","DOI":"10.1016\/S0021-9258(17)46766-4","volume":"268","author":"S Gr\u00fcne","year":"1993","unstructured":"Gr\u00fcne S, Engelking LR, Anwer MS (1993) Role of intracellular calcium and protein kinases in the activation of hepatic Na\u2009+\/taurocholate cotransport by cyclic AMP. J Biol Chem 268:17734\u201317741","journal-title":"J Biol Chem"},{"key":"2892_CR51","doi-asserted-by":"publisher","first-page":"G44","DOI":"10.1152\/ajpgi.00530.2001","volume":"283","author":"CRL Webster","year":"2002","unstructured":"Webster CRL, Blanch C, Anwer MS (2002) Role of PP2B in cAMP-induced dephosphorylation and translocation of NTCP. Am J Physiol Gastrointest Liver Physiol 283:G44\u2013G50","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2892_CR52","doi-asserted-by":"publisher","first-page":"33687","DOI":"10.1074\/jbc.M502151200","volume":"280","author":"MS Anwer","year":"2005","unstructured":"Anwer MS, Gillin H, Mukhopadhyay S, Balasubramaniyan N, Suchy FJ, Ananthanarayanan M (2005) Dephosphorylation of Ser-226 facilitates plasma membrane retention of Ntcp. J Biol Chem 280:33687\u201333692. https:\/\/doi.org\/10.1074\/jbc.M502151200","journal-title":"J Biol Chem"},{"key":"2892_CR53","doi-asserted-by":"publisher","first-page":"7213","DOI":"10.1074\/jbc.M305782200","volume":"279","author":"RH Ho","year":"2004","unstructured":"Ho RH, Leake BF, Roberts RL, Lee W, Kim RB (2004) Ethnicity-dependent polymorphism in Na+\u2009-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. J Biol Chem 279:7213\u20137222. https:\/\/doi.org\/10.1074\/jbc.M305782200","journal-title":"J Biol Chem"},{"key":"2892_CR54","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3109\/00498254.2011.555567","volume":"41","author":"W Pan","year":"2011","unstructured":"Pan W, Song I-S, Shin H-J, Kim M-H, Choi Y-L, Lim J, Kim W-Y, Lee S-S, Shin J-G (2011) Genetic polymorphisms in Na+\u2009-taurocholate co-transporting polypeptide (NTCP) and ileal apical sodium-dependent bile acid transporter (ASBT) and ethnic comparisons of functional variants of NTCP among Asian populations. Xenobiotica 41:501\u2013510. https:\/\/doi.org\/10.3109\/00498254.2011.555567","journal-title":"Xenobiotica"},{"key":"2892_CR55","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1128\/JVI.67.1.366-372.1993","volume":"67","author":"C Sureau","year":"1993","unstructured":"Sureau C, Guerra B, Lanford RE (1993) Role of the large hepatitis B virus envelope protein in infectivity of the hepatitis delta virion. J Virol 67:366\u2013372","journal-title":"J Virol"},{"key":"2892_CR56","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","volume":"64","author":"M Nassal","year":"2015","unstructured":"Nassal M (2015) HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut 64:1972\u20131984. https:\/\/doi.org\/10.1136\/gutjnl-2015-309809","journal-title":"Gut"},{"key":"2892_CR57","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.jhep.2016.02.009","volume":"64","author":"J Lucifora","year":"2016","unstructured":"Lucifora J, Protzer U (2016) Attacking hepatitis B virus cccDNA\u2014the holy grail to hepatitis B cure. J Hepatol 64:S41\u2013S48. https:\/\/doi.org\/10.1016\/j.jhep.2016.02.009","journal-title":"J Hepatol"},{"key":"2892_CR58","doi-asserted-by":"publisher","first-page":"6124","DOI":"10.1073\/pnas.77.10.6124","volume":"77","author":"M Rizzetto","year":"1980","unstructured":"Rizzetto M, Hoyer B, Canese MG, Shih JW, Purcellt RH, Gerin JL (1980) Delta agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. PNAS 77:6124\u20136128","journal-title":"PNAS"},{"key":"2892_CR59","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1016\/j.jhep.2016.02.013","volume":"64","author":"C Sureau","year":"2016","unstructured":"Sureau C, Negro F (2016) The hepatitis delta virus: replication and pathogenesis. J Hepatol 64:S102\u2013S116. https:\/\/doi.org\/10.1016\/j.jhep.2016.02.013","journal-title":"J Hepatol"},{"key":"2892_CR60","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.cell.2006.02.007","volume":"124","author":"M Marsh","year":"2006","unstructured":"Marsh M, Helenius A (2006) Virus entry: open sesame. Cell 124:729\u2013740. https:\/\/doi.org\/10.1016\/j.cell.2006.02.007","journal-title":"Cell"},{"key":"2892_CR61","doi-asserted-by":"publisher","first-page":"10460","DOI":"10.1128\/JVI.79.16.10460","volume":"79","author":"G Abou Jaoude","year":"2005","unstructured":"Abou Jaoude G, Sureau C (2005) Role of the antigenic loop of the hepatitis B virus envelope proteins in infectivity of hepatitis delta virus. J Virol 79:10460\u201310466. https:\/\/doi.org\/10.1128\/JVI.79.16.10460","journal-title":"J Virol"},{"key":"2892_CR62","doi-asserted-by":"publisher","first-page":"13057","DOI":"10.1128\/JVI.01495-07","volume":"81","author":"G Abou Jaoude","year":"2007","unstructured":"Abou Jaoude G, Sureau C (2007) Entry of hepatitis delta virus requires the conserved cysteine residues of the hepatitis B virus envelope protein antigenic loop and is blocked by inhibitors of thiol-disulfide exchange. J Virol 81:13057\u201313066. https:\/\/doi.org\/10.1128\/JVI.01495-07","journal-title":"J Virol"},{"key":"2892_CR63","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1128\/JVI.61.5.1672-1677.1987","volume":"61","author":"DH Persing","year":"1987","unstructured":"Persing DH, Varmus HE, Ganem DON (1987) The preS1 protein of hepatitis B virus is acylated at its amino terminus with myristic acid. J Virol 61:1672\u20131677","journal-title":"J Virol"},{"key":"2892_CR64","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1006\/viro.1995.0002","volume":"213","author":"P Gripon","year":"1995","unstructured":"Gripon P, Seyec JLE, Rumin S, Guguen-Guillouzo C (1995) Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity. Virology 213:292\u2013299","journal-title":"Virology"},{"key":"2892_CR65","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1006\/viro.1996.0209","volume":"218","author":"V Bruss","year":"1996","unstructured":"Bruss V, Hagelstein J, Gerhardt E, Galle PR (1996) Myristylation of the large surface protein is required for hepatitis B virus in vitro infectivity. Virology 218:396\u2013399","journal-title":"Virology"},{"key":"2892_CR66","doi-asserted-by":"publisher","first-page":"15655","DOI":"10.1073\/pnas.232137699","volume":"99","author":"P Gripon","year":"2002","unstructured":"Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, Guguen-Guillouzo C (2002) Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA. 99:15655\u201315660. https:\/\/doi.org\/10.1073\/pnas.232137699","journal-title":"Proc Natl Acad Sci USA."},{"key":"2892_CR67","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0300-9084(01)01290-1","volume":"83","author":"D Spillmann","year":"2001","unstructured":"Spillmann D (2001) Heparan sulfate: Anchor for viral intruders? Biochimie 83:811\u2013817","journal-title":"Biochimie"},{"key":"2892_CR68","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1017\/S1462399409001367","volume":"12","author":"AH Bartlett","year":"2015","unstructured":"Bartlett AH, Park PW (2015) Proteoglycans in host\u2013pathogen interactions: molecular mechanisms and therapeutic implications. Expert Rev Mol Med 12:e5. https:\/\/doi.org\/10.1017\/S1462399409001367","journal-title":"Expert Rev Mol Med"},{"key":"2892_CR69","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/hep.21896","volume":"46","author":"A Schulze","year":"2007","unstructured":"Schulze A, Gripon P, Urban S (2007) Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 46:1759\u20131768. https:\/\/doi.org\/10.1002\/hep.21896","journal-title":"Hepatology"},{"key":"2892_CR70","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/hep.26125","volume":"57","author":"C Sureau","year":"2013","unstructured":"Sureau C, Salisse J (2013) A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant. Hepatology 57:985\u2013994. https:\/\/doi.org\/10.1002\/hep.26125","journal-title":"Hepatology"},{"key":"2892_CR71","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/hep.28013","volume":"63","author":"ER Verrier","year":"2016","unstructured":"Verrier ER, Colpitts CC, Bach C, Heydmann L, Weiss A, Renaud M, Durand SC, Habersetzer F, Durantel D, Abou-Jaoud\u00e9 G, L\u00f3pez Ledesma MM, Felmlee DJ, Soumillon M, Croonenborghs T, Pochet N, Nassal M, Schuster C, Brino L, Sureau C, Zeisel MB, Baumert TF (2016) A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses. Hepatology 63:35\u201348. https:\/\/doi.org\/10.1002\/hep.28013","journal-title":"Hepatology"},{"key":"2892_CR72","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/j.1462-5822.2007.01023.x","volume":"10","author":"CM Leistner","year":"2008","unstructured":"Leistner CM, Gruen-Bernhard S, Glebe D (2008) Role of glycosaminoglycans for binding and infection of hepatitis B virus. Cell Microbiol 10:122\u2013133. https:\/\/doi.org\/10.1111\/j.1462-5822.2007.01023.x","journal-title":"Cell Microbiol"},{"key":"2892_CR73","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/0092-8674(86)90663-X","volume":"46","author":"AR Neurath","year":"1986","unstructured":"Neurath AR, Kent SBH, Strick N, Parker K (1986) Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 46:429\u2013436","journal-title":"Cell"},{"key":"2892_CR74","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1084\/jem.175.2.461","volume":"175","author":"BAR Neurath","year":"1992","unstructured":"Neurath BAR, Strick N, Sproul P (1992) Search for hepatitis B virus cell receptors reveals binding sites for interleukin 6 on the virus envelope protein. J Exp Med 175:461\u2013469","journal-title":"J Exp Med"},{"key":"2892_CR75","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1099\/0022-1317-73-8-2041","volume":"73","author":"P Pontisso","year":"1992","unstructured":"Pontisso P, Ruvoletto MG, Tiribelli C, Gerlich WH, Ruop A, Alberti A (1992) The preS1 domain of hepatitis B virus and IgA cross-react in their binding to the hepatocyte surface. J Gen Virol 73:2041\u20132045","journal-title":"J Gen Virol"},{"key":"2892_CR76","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1128\/JVI.74.1.110-116.2000","volume":"74","author":"CJ Ryu","year":"2000","unstructured":"Ryu CJ, Cho D, Gripon P, Kim HS, Guguen-Guillouzo C, Hong HJ (2000) An 80-kilodalton protein that binds to the Pre-S1 domain of hepatitis B virus. J Virol 74:110\u2013116","journal-title":"J Virol"},{"key":"2892_CR77","doi-asserted-by":"publisher","first-page":"36613","DOI":"10.1074\/jbc.M102377200","volume":"276","author":"Falco S De","year":"2001","unstructured":"De Falco S, Ruvoletto MG, Verdoliva A, Ruvo M, Raucci A, Marino M, Senatore S, Cassani G, Alberti A, Pontisso P, Fassina G (2001) Cloning and expression of a novel hepatitis B virus-binding protein from HepG2 cells. J Biol Chem 276:36613\u201336623. https:\/\/doi.org\/10.1074\/jbc.M102377200","journal-title":"J Biol Chem"},{"key":"2892_CR78","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1007\/s10620-005-2724-4","volume":"50","author":"D Li","year":"2005","unstructured":"Li D, Wang XZ, Ding J, Yu J-P (2005) NACA as a potential cellular target of hepatitis B virus PreS1 protein. Dig Dis Sci 50:1156\u20131160. https:\/\/doi.org\/10.1007\/s10620-005-2724-4","journal-title":"Dig Dis Sci"},{"key":"2892_CR79","doi-asserted-by":"publisher","first-page":"7176","DOI":"10.1128\/JVI.03533-12","volume":"87","author":"G Zhong","year":"2013","unstructured":"Zhong G, Yan H, Wang H, He W, Jing Z, Qi Y, Fu L, Gao Z, Huang Y, Xu G, Feng X, Sui J, Li W (2013) Sodium taurocholate cotransporting polypeptide mediates woolly monkey hepatitis B virus infection of tupaia hepatocytes. J Virol 87:7176\u20137184. https:\/\/doi.org\/10.1128\/JVI.03533-12","journal-title":"J Virol"},{"key":"2892_CR80","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/hep.27608","volume":"61","author":"L Peng","year":"2015","unstructured":"Peng L, Zhao Q, Li Q, Li M, Li C, Xu T, Jing X, Zhu X, Wang Y, Li F, Liu R, Zhong C, Pan Q, Zeng B, Liao Q, Hu B, Hu Z, Huang Y, Sham P, Liu J, Xu S, Wang J, Gao Z, Wang Y (2015) The p.Ser267Phe variant in SLC10A1 is associated with resistance to chronic hepatitis B. Hepatology 61:1251\u20131260. https:\/\/doi.org\/10.1002\/hep.27608","journal-title":"Hepatology"},{"key":"2892_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-17959-x","volume":"7","author":"HW Lee","year":"2017","unstructured":"Lee HW, Park HJ, Jin B, Dezhbord M, Kim DY, Han KH, Ryu WS, Kim S, Ahn SH (2017) Effect of S267F variant of NTCP on the patients with chronic hepatitis B. Sci Rep 7:1\u20137. https:\/\/doi.org\/10.1038\/s41598-017-17959-x","journal-title":"Sci Rep"},{"key":"2892_CR82","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy355\/5037696","author":"P An","year":"2018","unstructured":"An P, Zeng Z, Winkler CA (2018) The loss-of-function S267F variant in HBV receptor NTCP reduces human risk to HBV infection and disease progression. J Infect Dis. https:\/\/doi.org\/10.1093\/infdis\/jiy355\/5037696","journal-title":"J Infect Dis"},{"key":"2892_CR83","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1136\/gutjnl-2015-310686","volume":"65","author":"H Hu","year":"2016","unstructured":"Hu H, Liu J, Lin Y-L, Luo W, Chu Y-J, Chang C-L, Jen C-L, Lee M-H, Lu S-N, Wang L-Y, You S-L, Yang H-I, Chen C-J (2016) The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B. Gut 65:1514\u20131521. https:\/\/doi.org\/10.1136\/gutjnl-2015-310686","journal-title":"Gut"},{"key":"2892_CR84","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1478-3231.2005.01033.x","volume":"25","author":"G Zollner","year":"2005","unstructured":"Zollner G, Wagner M, Fickert P, Silbert D, Fuchsbichler A, Zatloukal K, Denk H, Trauner M (2005) Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int 25:367\u2013379. https:\/\/doi.org\/10.1111\/j.1478-3231.2005.01033.x","journal-title":"Liver Int"},{"key":"2892_CR85","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1128\/JVI.62.11.4136-4143.1988","volume":"62","author":"P Gripon","year":"1988","unstructured":"Gripon P, Diot C, Theze N, Fourel I, Loreal O, Brechot C, Guguen-Guillouzo C (1988) Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide. J Virol 62:4136\u20134143","journal-title":"J Virol"},{"key":"2892_CR86","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/hep.29112","volume":"66","author":"FA Lempp","year":"2017","unstructured":"Lempp FA, Wiedtke E, Qu B, Roques P, Chemin I, Vondran FWR, Le Grand R, Grimm D, Urban S (2017) Sodium taurocholate cotransporting polypeptide is the limiting host factor of hepatitis B virus infection in macaque and pig hepatocytes. Hepatology 66:703\u2013716","journal-title":"Hepatology"},{"key":"2892_CR87","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/j.jhep.2016.02.012","volume":"64","author":"L Allweiss","year":"2016","unstructured":"Allweiss L, Dandri M (2016) Experimental in vitro and in vivo models for the study of human hepatitis B virus infection. J Hepatol 64:S17\u2013S31. https:\/\/doi.org\/10.1016\/j.jhep.2016.02.012","journal-title":"J Hepatol"},{"key":"2892_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1004840","volume":"11","author":"W He","year":"2015","unstructured":"He W, Ren B, Mao F, Jing Z, Li Y, Liu Y, Peng B, Yan H, Qi Y, Sun Y, Guo J-T, Sui J, Wang F, Li W (2015) Hepatitis D virus infection of mice expressing human sodium taurocholate co-transporting polypeptide. PLoS Pathog 11:1\u201317. https:\/\/doi.org\/10.1371\/journal.ppat.1004840","journal-title":"PLoS Pathog"},{"key":"2892_CR89","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jhep.2015.10.030","volume":"64","author":"FA Lempp","year":"2016","unstructured":"Lempp FA, Mutz P, Lipps C, Wirth D, Bartenschlager R, Urban S (2016) Evidence that hepatitis B virus replication in mouse cells is limited by the lack of a host cell dependency factor. J Hepatol 64:556\u2013564. https:\/\/doi.org\/10.1016\/j.jhep.2015.10.030","journal-title":"J Hepatol"},{"key":"2892_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-01953-y","volume":"8","author":"BJ Burwitz","year":"2017","unstructured":"Burwitz BJ, Wettengel JM, M\u00fcck-H\u00e4usl MA, Ringelhan M, Ko C, Festag MM, Hammond KB, Northrup M, Bimber BN, Jacob T, Reed JS, Norris R, Park B, Moller-Tank S, Esser K, Greene JM, Wu HL, Abdulhaqq S, Webb G, Sutton WF, Klug A, Swanson T, Legasse AW, Vu TQ, Asokan A, Haigwood NL, Protzer U, Sacha JB (2017) Hepatocytic expression of human sodium-taurocholate cotransporting polypeptide enables hepatitis B virus infection of macaques. Nat Commun 8:1\u201310. https:\/\/doi.org\/10.1038\/s41467-017-01953-y","journal-title":"Nat Commun"},{"key":"2892_CR91","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1128\/JVI.79.3.1613","volume":"79","author":"P Gripon","year":"2005","unstructured":"Gripon P, Cannie I, Urban S (2005) Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol 79:1613\u20131622. https:\/\/doi.org\/10.1128\/JVI.79.3.1613","journal-title":"J Virol"},{"key":"2892_CR92","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nbt1389","volume":"26","author":"J Petersen","year":"2008","unstructured":"Petersen J, Dandri M, Mier W, L\u00fctgehetmann M, Volz T, von Weizs\u00e4cker F, Haberkorn U, Fischer L, Pollok J-M, Erbes B, Seitz S, Urban S (2008) Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 26:335\u2013341. https:\/\/doi.org\/10.1038\/nbt1389","journal-title":"Nat Biotechnol"},{"key":"2892_CR93","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jhep.2016.04.013","volume":"65","author":"A Blank","year":"2016","unstructured":"Blank A, Markert C, Hohmann N, Carls A, Mikus G, Lehr T, Alexandrov A, Haag M, Schwab M, Urban S, Haefeli WE (2016) First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol 65:483\u2013489. https:\/\/doi.org\/10.1016\/j.jhep.2016.04.013","journal-title":"J Hepatol"},{"key":"2892_CR94","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","volume":"65","author":"P Bogomolov","year":"2016","unstructured":"Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, Lehr T, Lempp FA, Wedemeyer H, Haag M, Schwab M, Haefeli WE, Blank A, Urban S (2016) Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib\/IIa study. J Hepatol 65:490\u2013498. https:\/\/doi.org\/10.1016\/j.jhep.2016.04.016","journal-title":"J Hepatol"},{"key":"2892_CR95","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S0168-8278(18)30224-1","volume":"68","author":"H Wedemeyer","year":"2018","unstructured":"Wedemeyer H, Bogomolov P, Blank A, Allweiss L, Dandri-Petersen M, Bremer B, Voronkova N, Sch\u00f6neweis K, Pathil A, Burhenne J, Haag M, Schwab M, Haefeli W-E, Wiesch JSZ, Alexandrov A, Urban S (2018) Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV\/HDV co-infection. J Hepatol 68:S3","journal-title":"J Hepatol"},{"key":"2892_CR96","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.jhep.2014.05.018","volume":"61","author":"A K\u00f6nig","year":"2014","unstructured":"K\u00f6nig A, D\u00f6ring B, Mohr C, Geipel A, Geyer J, Glebe D (2014) Kinetics of the bile acid transporter and hepatitis B virus receptor Na\u2009+\/taurocholate cotransporting polypeptide (NTCP) in hepatocytes. J Hepatol 61:867\u2013875. https:\/\/doi.org\/10.1016\/j.jhep.2014.05.018","journal-title":"J Hepatol"},{"key":"2892_CR97","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.antiviral.2014.03.017","volume":"106","author":"M Blanchet","year":"2014","unstructured":"Blanchet M, Sureau C, Labont\u00e9 P (2014) Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle. Antivir Res 106:111\u2013115. https:\/\/doi.org\/10.1016\/j.antiviral.2014.03.017","journal-title":"Antivir Res"},{"key":"2892_CR98","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.antiviral.2012.12.008","volume":"97","author":"J Lucifora","year":"2013","unstructured":"Lucifora J, Esser K, Protzer U (2013) Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes. Antivir Res 97:195\u2013197. https:\/\/doi.org\/10.1016\/j.antiviral.2012.12.008","journal-title":"Antivir Res"},{"key":"2892_CR99","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/0006-2952(93)90489-J","volume":"46","author":"SA Azer","year":"1993","unstructured":"Azer SA, Stacey H (1993) Differential effects of Cyclosporin A on the transport of bile acids by human hepatocytes. Biochem Pharmacol 46:813\u2013819","journal-title":"Biochem Pharmacol"},{"key":"2892_CR100","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1124\/dmd.105.008748.basolateral","volume":"34","author":"S Mita","year":"2006","unstructured":"Mita S, Suzuki H, Akita H, Hayashi H, Onuki R, Hofmann AF, Sugiyama Y (2006) Inhibition of bile acid transport across Na\u2009+\/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs. Drug Metab Dispos 34:1575\u20131581. https:\/\/doi.org\/10.1124\/dmd.105.008748.basolateral","journal-title":"Drug Metab Dispos"},{"key":"2892_CR101","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/hep.27694","volume":"62","author":"D Slijepcevic","year":"2015","unstructured":"Slijepcevic D, Kaufman C, Wichers CGK, Gilglioni EH, Lempp FA, Duijst S, de Waart DR, Oude Elferink RPJ, Mier W, Stieger B, Beuers U, Urban S, van de Graaf SFJ (2015) Impaired uptake of conjugated bile acids and hepatitis B virus Pres1-binding in Na+\u2009-taurocholate cotransporting polypeptide knockout mice. Hepatology 62:207\u2013219. https:\/\/doi.org\/10.1002\/hep.27694","journal-title":"Hepatology"},{"key":"2892_CR102","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/hep.27240","volume":"61","author":"M Vaz","year":"2015","unstructured":"Vaz M, Paulusma CC, Huidekoper H, De RuM, Lim C, Koster J, Ho-Mok K, Bootsma AH, Groen AK, Schaap FG, Oude Elferink RPJ, Waterham HR, Wanders RJA (2015) Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype. Hepatology 61:260\u2013267. https:\/\/doi.org\/10.1002\/hep.27240","journal-title":"Hepatology"},{"key":"2892_CR103","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/hep.28952","volume":"65","author":"S Tsukuda","year":"2017","unstructured":"Tsukuda S, Watashi K, Hojima T, Isogawa M, Iwamoto M, Omagari K, Suzuki R, Aizaki H, Kojima S, Sugiyama M, Saito A, Tanaka Y, Mizokami M, Sureau C, Wakita T (2017) A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins. Hepatology 65:1104\u20131116. https:\/\/doi.org\/10.1002\/hep.28952","journal-title":"Hepatology"},{"key":"2892_CR104","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature13117.Structure","volume":"509","author":"AG Khan","year":"2014","unstructured":"Khan AG, Whidby J, Miller MT, Scarborough H, Zatorski AV, Cygan A, Price AA, Yost SA, Bohannon CD, Jacob J, Grakoui A, Marcotrigiano J (2014) Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature 509:381\u2013384. https:\/\/doi.org\/10.1038\/nature13117.Structure","journal-title":"Nature"},{"key":"2892_CR105","doi-asserted-by":"publisher","first-page":"41003","DOI":"10.1074\/jbc.M302267200","volume":"278","author":"H Barth","year":"2003","unstructured":"Barth H, Sch\u00e4fer C, Adah MI, Zhang F, Linhardt RJ, Toyoda H, Kinoshita-Toyoda A, Toida T, van Kuppevelt TH, Depla E, von Weizs\u00e4cker F, Blum HE, Baumert TF (2003) Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 278:41003\u201341012. https:\/\/doi.org\/10.1074\/jbc.M302267200","journal-title":"J Biol Chem"},{"key":"2892_CR106","doi-asserted-by":"publisher","first-page":"6866","DOI":"10.1128\/JVI.03475-12","volume":"87","author":"Q Shi","year":"2013","unstructured":"Shi Q, Jiang J, Luo G (2013) Syndecan-1 serves as the major receptor for attachment of hepatitis C virus to the surfaces of hepatocytes. J Virol 87:6866\u20136875. https:\/\/doi.org\/10.1128\/JVI.03475-12","journal-title":"J Virol"},{"key":"2892_CR107","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1371\/journal.pone.0095550","volume":"9","author":"M Lefevre","year":"2014","unstructured":"Lefevre M, Felmlee DJ, Parnot M, Baumert TF, Schuster C (2014) Syndecan 4 is involved in mediating HCV entry through interaction with lipoviral particle-associated apolipoprotein E. PLoS One 9:3\u201310. https:\/\/doi.org\/10.1371\/journal.pone.0095550","journal-title":"PLoS One"},{"key":"2892_CR108","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1126\/science.282.5390.938","volume":"282","author":"P Pileri","year":"1998","unstructured":"Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S (1998) Binding of hepatitis C virus to CD81. Science 282:938\u2013942 (80-.)","journal-title":"Science"},{"key":"2892_CR109","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.virol.2009.08.037","volume":"394","author":"DM Owen","year":"2010","unstructured":"Owen DM, Huang H, Ye J, Gale M Jr (2010) Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low density lipoprotein receptor. Virology 394:99\u2013108. https:\/\/doi.org\/10.1016\/j.virol.2009.08.037","journal-title":"Virology"},{"key":"2892_CR110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hep.21994","volume":"46","author":"MB Zeisel","year":"2007","unstructured":"Zeisel MB, Koutsoudakis G, Schnober EK, Haberstroh A, Blum HE, Cosset F-L, Wakita T, Jaeck D, Doffoel M, Royer C, Soulier E, Schvoerer E, Schuster C, Stoll-Keller F, Bartenschlager R, Pietschmann T, Barth H, Baumert TF (2007) Scavenger receptor class B Type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology 46:1\u20133. https:\/\/doi.org\/10.1002\/hep.21994","journal-title":"Hepatology"},{"key":"2892_CR111","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/nm.2341","volume":"17","author":"J Lupberger","year":"2011","unstructured":"Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset F-L, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffo\u00ebl M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF (2011) EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 17:589\u2013595. https:\/\/doi.org\/10.1038\/nm.2341","journal-title":"Nat Med"},{"key":"2892_CR112","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1128\/JVI.06996-11","volume":"86","author":"MJ Farquhar","year":"2012","unstructured":"Farquhar MJ, Hu K, Harris HJ, Davis C, Brimacombe CL, Fletcher SJ, Baumert TF, Rappoport JZ, Balfe P, McKeating JA (2012) Hepatitis C virus induces CD81 and Claudin-1 endocytosis. J Virol 86:4305\u20134316. https:\/\/doi.org\/10.1128\/JVI.06996-11","journal-title":"J Virol"},{"key":"2892_CR113","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jhep.2014.06.031","volume":"61","author":"J Dubuisson","year":"2014","unstructured":"Dubuisson J, Cosset F-L (2014) Virology and cell biology of the hepatitis C virus life cycle\u2014An update. J Hepatol 61:S3\u2013S13. https:\/\/doi.org\/10.1016\/j.jhep.2014.06.031","journal-title":"J Hepatol"},{"key":"2892_CR114","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.celrep.2016.09.084","volume":"17","author":"ER Verrier","year":"2016","unstructured":"Verrier ER, Colpitts CC, Bach C, Heydmann L, Zona L, Xiao F, Thumann C, Crouchet E, Gaudin R, Sureau C, Cosset F-L, McKeating JA, Pessaux P, Hoshida Y, Schuster C, Zeisel MB, Baumert TF (2016) Solute carrier NTCP regulates innate antiviral immune responses targeting hepatitis C virus infection of hepatocytes. Cell Rep 17:1357\u20131368. https:\/\/doi.org\/10.1016\/j.celrep.2016.09.084","journal-title":"Cell Rep"},{"key":"2892_CR115","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.coviro.2013.11.004","volume":"4","author":"SE Smith","year":"2014","unstructured":"Smith SE, Weston S, Kellam P, Marsh M (2014) IFITM proteins\u2014cellular inhibitors of viral entry. Curr Opin Virol 4:71\u201377. https:\/\/doi.org\/10.1016\/j.coviro.2013.11.004","journal-title":"Curr Opin Virol"},{"key":"2892_CR116","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/hep.26066.IFITM1","volume":"57","author":"C Wilkins","year":"2013","unstructured":"Wilkins C, Woodward J, Lau DT-Y, Barnes A, Joyce M, McFarlane N, McKeating J, Tyrrell DL, Gale M Jr (2013) IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology 57:461\u2013469. https:\/\/doi.org\/10.1002\/hep.26066.IFITM1","journal-title":"Hepatology"},{"key":"2892_CR117","doi-asserted-by":"publisher","first-page":"25946","DOI":"10.1074\/jbc.M115.657346","volume":"290","author":"SK Narayana","year":"2015","unstructured":"Narayana SK, Helbig KJ, Mccartney EM, Eyre NS, Bull RA, Eltahla A, Lloyd AR, Beard MR (2015) The interferon-induced transmembrane proteins, IFITM1, IFITM2, and IFITM3 inhibit hepatitis C virus entry. J Biol Chem 290:25946\u201325959. https:\/\/doi.org\/10.1074\/jbc.M115.657346","journal-title":"J Biol Chem"},{"key":"2892_CR118","doi-asserted-by":"publisher","first-page":"9633","DOI":"10.1128\/JVI.00795-07","volume":"81","author":"K-O Chang","year":"2007","unstructured":"Chang K-O, George DW (2007) Bile acids promote the expression of hepatitis C virus in replicon-harboring cells. J Virol 81:9633\u20139640. https:\/\/doi.org\/10.1128\/JVI.00795-07","journal-title":"J Virol"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00018-018-2892-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-018-2892-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-018-2892-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T01:05:39Z","timestamp":1661735139000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00018-018-2892-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,10]]},"references-count":118,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["2892"],"URL":"https:\/\/doi.org\/10.1007\/s00018-018-2892-y","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,10]]},"assertion":[{"value":"26 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflicting interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}